Claims
- 1. A 1-acyl-2-oxindole-3-carboxamide compound of formula ##STR10## and the pharmaceutically-acceptable base salts thereof; wherein X and Y are each selected from the group consisting of hydrogen, fluoro, chloro, bromo, trifluoromethyl and alkyl having 1 to 4 carbons;
- R.sup.1 is selected from the group consisting of alkyl having from 1 to 6 carbons, cycloalkyl having from 3 to 7 carbons and groups of the formula ##STR11## wherein R.sup.3 and R.sup.4 are each selected from the group consisting of hydrogen, fluoro, chloro, alkyl having 1 to 4 carbons and trifluoromethyl;
- and R.sup.2 is alkyl having 1 to 6 carbons.
- 2. A compound according to claim 1, wherein R.sup.1 is said ##STR12##
- 3. A compound according to claim 2, wherein R.sup.2 is methyl.
- 4. A compound according to claim 3, wherein X and Y are each hydrogen.
- 5. The compound according to claim 4, wherein R.sup.1 is phenyl.
- 6. A compound according to claim 3, wherein X is 5-chloro and Y is hydrogen.
- 7. The compound according to claim 6, wherein R.sup.1 is 4-fluorophenyl.
- 8. The compound according to claim 6, wherein R.sup.1 is 2,4-dichlorophenyl.
- 9. A compound according to claim 3, wherein X is 5-chloro and Y is 6-fluoro.
- 10. The compound according to claim 9, wherein R.sup.1 is phenyl.
- 11. The compound according to claim 9, wherein R.sup.1 is 4-chlorophenyl.
- 12. A method of eliciting an analgesic response in a mammalian subject, which comprises administering to said subject an analgesic response eliciting amount of a 1-acyl-2-oxindole-3-carboxamide compound of the formula ##STR13## or a pharmaceutically-acceptable base salt thereof; wherein X and Y are each selected from the group consisting of hydrogen, fluoro, chloro, bromo, trifluoromethyl and alkyl having 1 to 4 carbons;
- R.sup.1 is selected from the group consisting of alkyl having from 1 to 6 carbons, cycloalkyl having from 3 to 7 carbons groups of the formula ##STR14## wherein R.sup.3 and R.sup.4 are each selected from the group consisting of hydrogen, fluoro, chloro, alkyl having 1 to 4 carbons, alkoxy having 1 to 4 carbons and trifluoromethyl;
- and R.sup.2 is alkyl having 1 to 6 carbons.
- 13. The method according to claim 12, wherein R.sup.1 is said ##STR15##
- 14. The method according to claim 13, wherein R.sup.2 is methyl.
- 15. The method according to claim 14, wherein X and Y are each hydrogen.
- 16. The method according to claim 15, wherein R.sup.1 is phenyl.
- 17. The method according to claim 14, wherein X is 5-chloro and Y is hydrogen.
- 18. The method according to claim 17, wherein R.sup.1 is 4-fluorophenyl.
- 19. The method according to claim 17, wherein R.sup.1 is 2,4-dichlorophenyl.
- 20. The method according to claim 14, wherein X is 5-chloro and Y is 6-fluoro.
- 21. The method according to claim 20, wherein R.sup.1 is phenyl.
- 22. The method according to claim 20, wherein R.sup.1 is 4-chlorophenyl.
- 23. A method of treating an inflammatory disease in a mammalian subject, which comprises administering to said mammalian subject an inflammatory disease treating amount of a 1-acyl-2-oxindole-3-carboxamide compound of the formula ##STR16## or a pharmaceutically-acceptable base salt thereof; wherein X and Y are each selected from the group consisting of hydrogen, fluoro, chloro, bromo, trifluoromethyl and alkyl having 1 to 4 carbons;
- R.sup.1 is selected from the group consisting of alkyl having from 1 to 6 carbons, cycloalkyl having from 3 to 7 carbons, and groups of the formula ##STR17## wherein R.sup.3 and R.sup.4 are each selected from the group consisting of hydrogen, fluoro, chloro, alkyl having 1 to 4 carbons, alkoxy having 1 to 4 carbons and trifluoromethyl;
- and R.sup.2 is alkyl having 1 to 6 carbons.
- 24. The method according to claim 23, wherein R.sup.1 is said ##STR18##
- 25. The method according to claim 24, wherein R.sup.2 is methyl.
- 26. The method according to claim 25, wherein X and Y are each hydrogen.
- 27. The method according to claim 26, wherein R.sup.1 is phenyl.
- 28. The method according to claim 25, wherein X is 5-chloro and Y is hydrogen.
- 29. The method according to claim 28, wherein R.sup.1 is 4-florophenyl.
- 30. The method according to claim 28, wherein R.sup.1 is 2,4-dichlorophenyl.
- 31. The method according to claim 25, wherein X is 5-chloro and Y is 6-fluoro.
- 32. The method according to claim 31, wherein R.sup.1 is phenyl.
- 33. The method according to claim 31, wherein R.sup.1 is 4-chlorophenyl.
- 34. A pharmaceutical composition, which comprises a pharmaceutically-acceptable carrier and a 1-acyl-2-oxindole-3-carboxamide compound according to claim 1, and wherein the weight ratio of the pharmaceutically-acceptable carrier to the 1-acyl-2-oxindole-3-carboxamide compound is in the range from 1:4 to 4:1.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation in part of application Ser. No. 821,296, filed Jan. 22, 1986, now abandoned, which is a continuation in part of application Ser. No. 753,200 filed July 9,1985, now abandoned.
US Referenced Citations (4)
Non-Patent Literature Citations (2)
Entry |
Tacconi, et al., Tetrahedron, 27, (1971) pp. 561-579. |
C.A., 51:5044a (1957), Kisteneva. |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
821296 |
Jan 1986 |
|
Parent |
753200 |
Jul 1985 |
|